ABSTRACT
In this chapter, we will study the more complex Bayesian dose-finding mod-
els in two dimensions. Either the outcome has two dimensions (efficacy and
toxicity) or the treatment has two dimensions (drug combinations). Going
from phase-I to phase-II trials, the objectives gradually switch shift from
a single toxicity issue to the combination of toxicity and efficacy, while a
combination of drugs is a common way of treating progressive disease such
as cancer and AIDs in phase-II and phase-III trials.
